1. Home
  2. MRKR vs KPLT Comparison

MRKR vs KPLT Comparison

Compare MRKR & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • KPLT
  • Stock Information
  • Founded
  • MRKR N/A
  • KPLT 2012
  • Country
  • MRKR United States
  • KPLT United States
  • Employees
  • MRKR N/A
  • KPLT N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • KPLT Diversified Commercial Services
  • Sector
  • MRKR Health Care
  • KPLT Consumer Discretionary
  • Exchange
  • MRKR Nasdaq
  • KPLT Nasdaq
  • Market Cap
  • MRKR 30.7M
  • KPLT 33.2M
  • IPO Year
  • MRKR N/A
  • KPLT N/A
  • Fundamental
  • Price
  • MRKR $3.47
  • KPLT $6.01
  • Analyst Decision
  • MRKR Strong Buy
  • KPLT Hold
  • Analyst Count
  • MRKR 1
  • KPLT 2
  • Target Price
  • MRKR $19.00
  • KPLT $12.00
  • AVG Volume (30 Days)
  • MRKR 91.1K
  • KPLT 24.0K
  • Earning Date
  • MRKR 11-14-2024
  • KPLT 11-06-2024
  • Dividend Yield
  • MRKR N/A
  • KPLT N/A
  • EPS Growth
  • MRKR N/A
  • KPLT N/A
  • EPS
  • MRKR N/A
  • KPLT N/A
  • Revenue
  • MRKR $5,395,849.00
  • KPLT $241,789,000.00
  • Revenue This Year
  • MRKR $35.94
  • KPLT $12.92
  • Revenue Next Year
  • MRKR N/A
  • KPLT $6.30
  • P/E Ratio
  • MRKR N/A
  • KPLT N/A
  • Revenue Growth
  • MRKR 79.04
  • KPLT 14.99
  • 52 Week Low
  • MRKR $2.44
  • KPLT $5.79
  • 52 Week High
  • MRKR $6.16
  • KPLT $23.54
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 50.16
  • KPLT 42.80
  • Support Level
  • MRKR $3.47
  • KPLT $5.88
  • Resistance Level
  • MRKR $5.95
  • KPLT $6.50
  • Average True Range (ATR)
  • MRKR 0.63
  • KPLT 0.45
  • MACD
  • MRKR 0.01
  • KPLT 0.00
  • Stochastic Oscillator
  • MRKR 16.99
  • KPLT 25.31

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

Share on Social Networks: